Black Diamond Therapeutics (BDTX) Free Cash Flow (2019 - 2026)
Black Diamond Therapeutics (BDTX) posted Free Cash Flow of -$10.2 million for Q1 2026, down 51.09% on a QoQ basis from -$6.7 million in Q4 2025, and down 119.06% year-over-year from $53.5 million in Q1 2025.
Black Diamond Therapeutics (BDTX) Free Cash Flow (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$10.2 million for Q1 2026.
- Quarterly Free Cash Flow fell 119.06% year-over-year to -$10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.9 million (down 379.75% YoY) and the FY2025 annual result came in at $29.8 million, up 147.62% from the prior year.
- Free Cash Flow was -$10.2 million for Q1 2026 at Black Diamond Therapeutics, down from -$6.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $53.5 million in Q1 2025 and bottomed at -$28.6 million in Q1 2022.
- A 5-year average of -$11.5 million and a median of -$15.0 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow soared 352.15% — and 2026, when it slumped 119.06%.
- Black Diamond Therapeutics' Free Cash Flow stood at -$21.9 million in 2022, then surged by 36.24% to -$14.0 million in 2023, then fell by 7.31% to -$15.0 million in 2024, then jumped by 55.08% to -$6.7 million in 2025, then sank by 51.09% to -$10.2 million in 2026.
- Business Quant data shows BDTX's Free Cash Flow at -$10.2 million in Q1 2026, -$6.7 million in Q4 2025, and -$7.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.95 Mn |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | -10.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.19 Mn |
| Mar 31, 2026 | -10.19 Mn |
| Dec 31, 2025 | -6.74 Mn |
| Dec 31, 2025 | -6.74 Mn |
| Sep 30, 2025 | -7.81 Mn |
| Sep 30, 2025 | -7.81 Mn |
| Jun 30, 2025 | -9.12 Mn |
| Jun 30, 2025 | -9.12 Mn |
| Mar 31, 2025 | 53.45 Mn |
| Mar 31, 2025 | 53.45 Mn |
| Dec 31, 2024 | -15.01 Mn |
| Dec 31, 2024 | -15.01 Mn |
| Sep 30, 2024 | -11.28 Mn |
| Sep 30, 2024 | -11.28 Mn |
| Jun 30, 2024 | -15.06 Mn |
| Jun 30, 2024 | -15.06 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Mar 31, 2024 | -21.20 Mn |
| Dec 31, 2023 | -13.99 Mn |
| Dec 31, 2023 | -13.99 Mn |